Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment.
about
Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapyMeta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapyAgreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysisEvaluating the response of neoadjuvant chemotherapy for treatment of breast cancer: are tumor biomarkers and dynamic contrast enhanced MR images useful predictive tools?Phosphorylation of p90RSK is associated with increased response to neoadjuvant chemotherapy in ER-positive breast cancer.The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic reviewNeoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging.Diagnostic performance of magnetic resonance imaging for assessing tumor response in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy is associated with molecular biomarker profile.Three-dimensional Contrast-enhanced Ultrasound in Response Assessment for Breast Cancer: A Comparison with Dynamic Contrast-enhanced Magnetic Resonance Imaging and Pathology.Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).Neoadjuvant chemotherapy for early breast cancer.Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.Triple-negative breast cancer--current status and future directions.Impact of factors affecting the residual tumor size diagnosed by MRI following neoadjuvant chemotherapy in comparison to pathology.Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer?Imaging of triple-negative breast cancer.Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.Residual Mammographic Microcalcifications and Enhancing Lesions on MRI After Neoadjuvant Systemic Chemotherapy for Locally Advanced Breast Cancer: Correlation with Histopathologic Residual Tumor Size.Diagnostic performance of breast-specific gamma imaging in the assessment of residual tumor after neoadjuvant chemotherapy in breast cancer patients.Estrogen receptor status confers a distinct pattern of response to neoadjuvant chemotherapy: implications for optimal durations of therapy: distinct patterns of response according to ER expression.Clinical application of magnetic resonance imaging in management of breast cancer patients receiving neoadjuvant chemotherapy.Magnetic resonance imaging and ultrasonography in predicting infiltrating residual disease after preoperative chemotherapy in stage II-III breast cancer.Correlations between molecular subtypes and pathologic response patterns of breast cancers after neoadjuvant chemotherapy.Performance of Mid-Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer Subtype.
P2860
Q27024544-430EA6EC-9038-49DE-ACEA-2D808BABAB04Q27027281-F1D51446-5476-49A0-8976-883D476CF1BEQ30401252-8A841CB0-B66D-4A1C-870F-22572D28CDC4Q33814616-D8069FEB-6EA6-43C6-9FDE-0AF3C7F4B8DBQ34502227-C570574C-EAFB-4540-A702-3BAF40578481Q34566213-A3836075-7B84-4F9B-916E-16D3AE448108Q34940150-8406152B-E3B7-4E75-B681-EEB2ED5B6CC2Q35928203-EF2E9CEA-AA26-4C3B-8B5F-82510BA648C1Q37274051-52EE6A75-4F87-4D17-A570-331034664F10Q37300368-8962C3E2-09E8-4BEF-A4EE-156451552ED2Q37510892-998159C6-52E8-4D9A-A92E-6FE5EAE276BFQ37612288-FD60C1F1-ABC6-4817-B662-B24A8636358DQ37630082-EA463AC5-2365-48EC-80C6-5915FB25817BQ37734922-8B28D0EF-25EA-4D9A-9F44-2A442130DF6EQ38000076-D99497F0-DAC7-44D9-8A0A-E5F3B642C9B4Q38046577-B10580DB-CDE6-49D3-AD96-50A6D95DB242Q38250247-DACA623B-8DE2-4D76-A9AA-B95604D14A81Q38420000-2AC0F9EA-F718-4729-AAB3-48C1755B4525Q38439990-C16E08A8-CC86-4C4F-91B6-FF2E631EF1BAQ38461102-7FC493C8-6C44-4CC5-B36B-0CFA1AA3DFC9Q44491240-5A3916CC-84DE-4753-931B-83951D886899Q53080309-1008E23E-F32E-4E0D-997E-67CDDEFF823BQ54324778-2ECBF973-6E5A-4394-AD64-286462A45BB7Q55003756-01B62D55-7077-4578-A796-99036800752A
P2860
Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Age and HER2 expression status ...... o-adjuvant systemic treatment.
@en
type
label
Age and HER2 expression status ...... o-adjuvant systemic treatment.
@en
prefLabel
Age and HER2 expression status ...... o-adjuvant systemic treatment.
@en
P2093
P356
P1433
P1476
Age and HER2 expression status ...... o-adjuvant systemic treatment.
@en
P2093
P304
P356
10.1093/ANNONC/MDN683
P577
2009-01-29T00:00:00Z